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Background: Our previous studies demonstrated that S100A16 promotes adipogenesis and is involved in weight gain
attenuation induced by dietary calcium. Till now, the function of S100A16 in the breast cancer remains to be elucidated.
Results: In this study, we observed that S100A16 was expressed in higher levels in human breast cancer tissues
compared with paired adjacent non-cancerous tissues. Further examination showed that overexpression of S100A16 in
MCF-7 cells could increase cell proliferation and colony formation. One major mechanistic change was that S100A16 was
able to up-regulate the transcription factors Notch1, ZEB1, and ZEB2, which had the capacities to directly repress the
expression of epithelial markers E-cadherin and β-catenin but increase mesenchymal markers N-cadherin and vimentin, a
characterized phenotype of epithelial-mensenchymal transition (EMT). In addition to display with morphologic change,
migration and invasion were increased in S100A16 over-expressed MCF-7 cells. Importantly, knockdown of Notch1 by
specific siRNA could reverse the EMT induced by S100A16 overexpression, which confirmed that Notch1 played a critical
role in the process of EMT induced by S100A16.
Conclusions: All together, our data indicated that S100A16 had a potential function to regulate some embryonic
transcription factors to promote EMT in breast cancer cells which may be an important target site for the therapy of
breast cancer.
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Breast cancer is a worldwide malignant disease. Although
disease-free survival and overall survival have been signifi-
cantly improved, there are still some parts of patients diag-
nosed with metastases after systemic therapies [1]. The
poor survival of advanced breast cancer is related to the
lack of effective therapies, which can be attributed to poor
understanding of the molecular mechanisms underlying
the progression of disease toward invasion and metastasis
[2,3]. Up to now, many molecular markers have been
found, such as estrogen receptor (ER), progesterone* Correspondence: liuyun@njmu.edu.cn; ws0801@hotmail.com
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unless otherwise stated.receptor (PR) and HER2. ER and/or PR positive are con-
sidered as hormone receptor positive (HR+), which is a
predictor of endocrine therapy and good clinical outcome.
HER2 is an indicator of targeted therapy and a predictor
of poor clinical outcome. However, there is huge desire to
improve the survival of advanced breast cancer. Therefore,
it is important to identify new predictive biomarkers, espe-
cially those indicators for invasiveness of the disease.
S100A16 is a novel low-affinity calcium-binding protein
of the EF-hand superfamily [4-6]. Our previous studies sug-
gest that S100A16 promotes adipogenesis and is involved
in weight gain attenuation induced by dietary calcium [7,8].
Importantly, S100A16 is a ubiquitously expressed protein,
which is up-regulated in various malignant tumors [5,9].
However, the physiological functions of S100A16 in malig-
nant tumors are still undefined.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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crucial role in the formation and differentiation of mul-
tiple tissues. Importantly, it is clear that EMT is involved
in metastatic events in cancer and highly relevant to
tumor progression [10]. Notch signaling pathway affects
cancer patient survival, especially for Notch1 and Notch4
receptors [11]. Activation of the Notch signaling pathway
participates in EMT induction [12,13].
All of these findings imply that S100A16 may be in-
volved in the progression of breast cancer. To investigate
the function of S100A16 in breast cancer, we first docu-
mented here that S100A16 was over-expressed in breast
cancer tumors. Further examination demonstrated that
up-regulation of S100A16 promoted EMT via Notch1
pathway in breast cancer cell line MCF-7. Our results
suggested that S100A16 may be involved in the progress
of breast cancer.
Methods
RNA extraction, reverse transcription and quantitative
RT-PCR
The Trizol reagent (Invitrogen) was used to isolate total
RNA following manufacturer’s instructions. Then RNA
was used for cDNA synthesis using a reverse transcriptase
reaction kit (TaKaRa). Quantitative RT-PCR for β-actin
and other genes was performed for every cDNA sample.
All PCR reactions were performed using the fluorescent
SYBR Green I methodology. Real-time quantitative PCR
was performed with SYBR Premix Ex Taq (TaKaRa) ac-
cording to the manufacturer’s instructions. β-actin was
used as a loading control.
S100A16 expression was measured in 20 breast cancer
tissue samples compared with paired adjacent non-
cancerous tissue using qRT-PCR. The paired non-
cancerous tissues were adjacent non- cancerous tissue,
which were at least 5 cm away from the cancerous tis-
sue, which were normal “histologically”. This study was
approved by the ethics commit of the First Affiliated
Hospital with Nanjing Medical University. All patients
provided written informed consent for their clinical in-
formation to be reviewed by us. And it was in compli-
ance with the Helsinki Declaration.
Cell culture
The human breast cancer cell lines MCF-7, T47D, BT474,
ZR-75-1, MDA-MB-231, BT549, MCF10A, 184A1 and
184B5 were obtained from the American Tissue Culture
Collection (ATCC), and cultured in complete medium
(DMEM, IMEM or 1640 supplemented with 10% fetal bo-
vine serum) in a 5% CO2 37°C incubator.
Plasmid construction and lentivirus packaging
S100A16 gene was cloned by RT-PCR from RNA of human
MCF-7 cells and cloned into the pLV-GFP vector (a giftfrom Dr. Beicheng Sun, Nanjing Medical University,
China) using BamHIand MluI sites, named pLV-S100A16.
Plasmid sequencing was performed by Invitrogen Company
with a 3730 DNA analyzer. Primer sequences for S100A16:
Forward: TTGGATCCGGAGATGTCAGACTGCTACAC,
Reverse: TTACGCGTAAAGGGGTCTCTAGCTGCTG.
Recombinant lentivirus was generated from 293 T cells
using calcium phosphate precipitation. The levtivirus was
then transduced into MCF-7 and T47D cells mediated by
polybrene (8 μg/ml). Plain pLV-GFP lentivirus infected
MCF-7 and T47D cells were used as the control.
Colony formation assay
Cells used for colony formation analysis were seeded
into 6-well plates (1000 cells/ml) and cultured normally
for two weeks. The colonies were fixed in paraform and
stained with Giemsa after washed with PBS twice. The
number of colonies was counted.
MTT assay
MTT assay was applied to assess cell proliferation as de-
scribed previously [14]. Cell proliferation was compared
at five time point (1, 2, 3, 4, and 5 days) after the cells
were seeded. The absorbance of the samples was mea-
sured at 490 nm on a scanning multi-well spectropho-
tometer. Each experiment was repeated three times.
Cell migration and invasion assay
In vitro cell migration and invasion assays were per-
formed as described previously [15]. Cells growing in the
log phase were trypsinized, re-suspended in serum-free
medium, and seeded into Boyden chamebers (8 μm pore
size with polycarbonate membrane). The chambers
were then inserted into transwell apparatus (Costar,
Cambridge, MA, USA). The chambers were coated with
Matrigel (BD Biosciences, San Jose, USA) when cell in-
vasion assay was done. And the chambers were coated
without Matrigel when cell migration assay was done.
Medium with 10% FBS (600 μl) was added to the lower
chamber. After incubation of 24 h, cells on the top sur-
face of the insert were removed by wiping with cotton
swab. Cells that migrated to the bottom surface of the
insert were stained in 0.1% crystal violet for 30 min,
rinsed in PBS and then subjected to microscopic inspec-
tion. Images of three random fields (10×) were captured
from each membrane, and the number of migratory or
invasive cells was counted. Triplicate assays were used
for each experiment.
Notch1 small interfering RNA transfection
Notch1 siRNA were purchased from GenePharma
(Shanghai, China). MCF7-S10016 cells were transfected
with Notch1 siRNA as described previously [14]. The se-
quences of Notch1 were GUC CAG GAA ACA ACU
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GGA CTT (antisense), respectively. The sequences of
negative control were UUC UCC GAA CGU GUC ACG
UTT (sense) and ACG UGA CAC GUU CGG AGA
ATT (antisense), respectively.
Western blot analysis
Western blot analysis was performed as described previ-
ously [14]. Monoclonal anti-S100A16 (R&D), ZEB1
(Santa Cruz), ZEB2, Notch1 (Abcam), β-Catenin, N-
Cadherin, E-cadherin, Vimentin were purchased. GAPDH
(Santa Cruz) was used to as loading control. The intensity
of the bands was determined by using densitometric ana-
lysis. All experiments were performed three times.Immunohistochemistry and Fluorescence in situ
hybridization
Breast tissue samples were obtained at the time of surgery.
Immunohistochemistry (IHC) analyses were performed on
4 μm, formalin-fixed, paraffin-embedded slides from
breast cancer tissues and matched non-cancerous tissues.
Paraffin-embedded tissue sections were deparaffinized,
rehydrated, rinsed, and immersed in 10 mM sodium cit-
rate (pH 6.0) for antigen retrieval under high pressure in a
pressure cooker for 3 minutes. After treated with in
methanol containing 3% hydrogen peroxide for 10 min to
block endogenous peroxidase activity, the slides were in-
cubated with primary antibody for 1 hour at 37°C. After
washing, sequential incubations were performed with
horseradish peroxidase (HRP) conjugated antibodies (Invi-
trogen) for 30 min at room temperature. The stain was vi-
sualized using DAB Plus (Dako) and hematoxylin
counterstain. The expressions of S100A16, ER, PR, HER2
were all detected by IHC.
A Fluorescence in situ hybridization (FISH) test for
HER2 gene amplification was routinely ordered when
HER2 was IHC 2+. FISH was performed using the Path-
Vysion HER2 DNA FISH Kit (Vysis Inc, Downers Grove,
IL), according to the manufacturer’s instructions.Immunofluorescence
Cells were seeded in a 6-well culture plate. The cells
were immunofluorescence-labeled according to the
manufacturer’s instructions. Cells were incubated with
a blocking buffer for 1 hour to suppress non-specific
binding after washing and fixing. And then, cells were
incubated with primary antibody (ZEB1, ZEB2, β-
Catenin, N-Cadherin, E-cadherin, Vimentin) at 4°C
overnight, followed by incubation with a secondary
antibody for 1 hour. Cells were further mounted with
DAPI (4′, 6-diamidino-2-phenylindole) for 5 minutes
and analyzed using fluorescence microscopy.Luciferase reporter assay
We analyzed the putative promoter region of Notch1
(−1998 to +76) using a luciferase reporter assay. The
Notch1 promoter was cloned by PCR from genomic
DNA of human MDA-MB-231 cells. PCR-based clon-
ing was used to generate different segments (−483
to +76, −998 to +76, −1496 to +76, and −1998 to +76)
of the Notch-1 gene promoter. Then the amplified
products were ligated into the pGL3 basic vector using
NheI and XhoI sites (New England Biolab, UK), re-
spectively, named pGL3-Notch1-I, pGL3-Notch1-II,
pGL3-Notch1-III, and pGL3-Notch1-IV. Plasmid se-
quencing was performed by Invitrogen Company
(China) with a 3730 DNA analyzer. Primer sequences










For the S100A16 responsive promoter activity,
S100A16-transduced MCF-7 cells, MCF7-S100A16
cells were chosen to analyze the putative promoter re-
gion of Notch1 (−1998 to +76) using dual luciferase
reporter assay. MCF7-S100A16 cells were seeded into
6-well culture plates 1 day prior to transient transfection.
Plasmids pGL3-Notch1-I, pGL3-Notch1-α, pGL3-Notch1-
β, and pGL3-Notch1-Ις were respectively co-transfected
with the Renilla luciferase expression plasmid into MCF7-
S100A16 cells. After 48 h transfection, cells were col-
lected and luciferase activity was measured using the
Dual Luciferase Reporter Assay System (Promega,
USA) according to the manufacturer’s instructions.
Then, the cells were harvested and processed for dual-
luciferase reporter activity, in which the firefly lucifer-
ase activity was normalized by renilla luciferase
activity.Statistical analysis
All experiments in this study were repeated in tripli-
cate. Paired t-test was applied to calculate the statis-
tical significance of the expression levels of S100A16
mRNA in breast cancer tissue and adjacent non-
cancerous tissue. Student t test was applied to calcu-
late the statistical significance of other experimental
results. A significant difference was concluded for
P < 0.05.
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S100A16 was overexpressed in human breast
cancer tissues
We measured S100A16 expression in 20 breast cancer
tissue samples compared with paired adjacent non-
cancerous tissue using qRT-PCR. The clinical characteris-
tics of all subjects are summarized in Table 1. Of these 20
paired samples, 14 showed significantly higher S100A16
mRNA expression in the cancer tissue compared with the
adjacent tissue (Figure 1A). There was no significant dif-
ference of S100A16 mRNA levels between subgroups of
breast cancer with different ER, PR or HER2 status (data
not shown). The mean expression level of S100A16
mRNA in breast cancer tissue was also significantly higher
than that in adjacent non-cancerous tissue using a scatter
plot (Figure 1B). Besides, Immunostainings for S100A16
were performed in breast cancer tissues and the matched
non-cancerous tissues. Interestingly, over-expression of
S100A16 was observed particularly in the invasive front in
breast cancer tissues (Figure 1D), which indicated that
S100A16 might be related to EMT. To further study the
expression of S100A16 in breast cancer, S100A16 proteinTable 1 Characteristics of the 20 patients with breast cancer
Variables Cases
No. %




≤2 cm 9 45















Triple negative 4 20
HER2+ 6 30
HR+, ER and/or PR positive.expression was detected by Western blot in eight human
breast cancer cell lines versus three normal breast
epithelial cell lines (MCF10A, 184A1 and 184B5). It
was expressed in two ER positive cell lines MCF-7 and
ZR-75-1 (ER positive and HER2 negative cell lines)
(Figure 1C) and two ER negative cell lines MDA-MB-
468 (triple negative cell line) and SK-BR3 (HER2 amplified
cell line) (Figure 1C). Additionally, lower expression level
of S100A16 was also detected in BT474 (ER positive
and HER2 overexpression cell line) and MCF10A cells
(Figure 1C). S100A16 protein expression was not de-
tected in other two normal breast epithelial cell lines
184A1 and 184B5 (Additional file 1: Figure S1). Among
these limited cell lines, there was no direct correlation
between S100A16 and ER levels or HER2 expression al-
though relative levels of S100A16 in MDA-MB-468 and
SK-BR3 were higher compared with expressed ER posi-
tive cells (Figure 1C).
Up-regulation of S100A16 increased the capacities of
migration and invasion in MCF-7 and T47D cells
The results of clinical samples indicated that S100A16
may be associated with aggressive behavior in breast can-
cer (Figure 1A and B). To validate this, we overexpressed
S100A16 using pLV-S100A16 lentivirus in MCF-7 and
T47D cells. The protein levels of S100A16 were elevated
after infection with pLV-S100A16 lentivirus (Figure 2A and
Additional file 1: Figure S2). The new cell lines were named
as MCF7-S100A16 and T47D-S100A16, and the control
cell lines were named as MCF7-GFP and T47D-GFP.
The cell proliferation rate was increased after S100A16
overexpression (Figure 2B). And up-regulation of
S100A16 markedly increased the number of MCF-7 cell
colonies (Figure 2C). Furthermore, up-regulation of
S100A16 increased cell migration (Figure 2D and
Additional file 1: Figure S3) and invasion (Figure 2E
and Additional file 1: Figure S4) abilities compared
with control cells, which were evaluated by specific
transwell chambers. All of these results demonstrated
that up-regulation of S10016A made cells in an aggres-
sive phenotype.
Overexpression of S100A16 promoted EMT in MCF-7
and T47D cells
S100A16 over-expressed MCF-7 cells displayed mor-
phologic changes with a spindle-like shape (Figure 3A)
(similar changes were founded for T47D-S100A16
cells, data not shown). Up-regulation of S100A16 also
disrupted E-cadherin mediated cell-cell adhesion. We
observed that epithelial markers E-cadherin and β-
Catenin were significantly reduced in mRNA and pro-
tein levels in MCF7-S100A16 cells compared with
MCF7-GFP cells (Figure 3B and C) and T47D-GFP
cells (Additional file 1: Figure S2). In contrast,
Figure 1 S100A16 expression in tissues and cell lines. (A) qRT-PCR analysis of S100A16 expression in 20 pairs of breast cancer tissue and
adjacent tissue. Of these 20 pairs of tissues, 14 showed significantly higher S100A16 mRNA expression in the cancer tissue compared with the
adjacent tissue (P < 0.05). (B) A scatter plot showed the mean expression level of S100A16 mRNA in breast cancer tissue was significantly higher
than that in adjacent non-cancerous tissue (*P < 0.05 by paired t-test). (C) Western blot analysis of S100A16 expression in eight breast cancer cell
lines and a normal breast cell line MCF10A. It was expressed in MCF10A and five breast cancer lines including MCF-7. (D) Representative examples of
immunostaining (×400). In non-cancerous tissue, few S100A16 immunostaining was observed, while the expression of S100A16 was significantly higher
in cancerous tissue than non-cancerous tissue, especially in the invading front of cancerous tissue.
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significantly up-regulated in MCF7-S100A16 cells (Figure 3B
and C) and T47D-S100A16 cells (Additional file 1: Figure
S2), indicating a characterized feature of EMT.
Consistently, the epithelial and mesenchymal markers
were also examined by immunofluorescence staining.
Both E-cadherin and β-catenin resided in the cellmembrane and the intensity of fluorescence were re-
duced in MCF7-S100A16 cells compared with MCF7-
GFP cells (Figure 3D), whereas the mesenchymal
markers Vimentin and N-cadherin were increased by
S100A16 (Figure 3E). All of these data suggested that
S100A16 was able to repress E-cadherin to promote
EMT.
Figure 2 Up-regulation of S100A16 increased the capacities of proliferation, migration and invasion in MCF-7 cells. (A) S100A16 was
transfected in MCF-7 cells. Western blot was used to measure S100A16 protein expression in control cells (MCF7-GFP) and S100A16 overexpression cells
(MCF7-S100A16). (B) MTT assay showed that the cell proliferation rate was increased after S100A16 overexpression in MCF-7 cells (Bars, mean ± SD,
*P < 0.05, **P < 0.01). (C) Colony formation assay confirmed that up-regulation of S100A16 markedly increased the number of cell colonies in MCF-7
cells (P < 0.05). (D, E) Transwell migration and invasion assays showed that up-regulation of S100A16 increased cell migration (D) and invasion
(E) abilities compared with control cells (P < 0.05). Triplicate assays were used for each experiment (Magnification, 10×).
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ZEB 2 expression
It has been reported that Notch signaling pathway is in-
volved in EMT induction [12,13] and Notch1 is a prog-
nosis marker for breast cancer [11]. The transcription
factors ZEB1 and ZEB2 are known to repress E-cadherin
in various cells [16-18]. To determine whether these
transcriptional factors were regulated by S100A16, we
observed that Notch1 mRNA and protein levels both
were significantly enhanced in MCF7-S100A16 cells
(Figure 4A and B) (similar changes were founded for
T47D-S100A16 cells, data not shown). Consistently,
ZEB1 and ZEB2 in MCF7-S100A16 cells were significantly
higher than that in MCF7-GFP cells (Figure 4A and B).
Two transcription factors ZEB1 and ZEB2 localized in the
nucleus and the fluorescence signals were enhanced after
S100A16 up-regulation (Figure 4C and D). These results
demonstrated that up-regulation of S100A16 could in-
crease transcription factors to induce EMT.
Knockdown of Notch1 reversed EMT by decreasing ZEB1
and ZEB 2 expression
As shown in Figure 4A and B, S100A16 had ability to
promote EMT through regulation of ZEB1 and ZEB2.
Our previous study [19] suggests Notch1 is involved inthe induction of EMT in a novel breast cancer mouse
model containing human breast and human bone. Here, we
hypothesized that S100A16 may promote EMT through
Notch1/ZEB signaling pathways. To investigate the role of
Notch1, specific siRNA was used to knock down Notch1 in
MCF7-S100A16 cells (Figure 5A and B). Transcription fac-
tors ZEB1 and ZEB2 were significantly reduced in mRNA
and protein levels after knockdown of Notch1 (Figure 5A
and B). Consequently, epithelial markers E-cadherin and β-
catenin were significantly increased but mesenchymal
markers Vimentin and N-cadherin were reduced. There
was no variation in the expression of S100A16 influenced
by Notch1 knockdown, which indicated that S100A16 was
the upstream of Notch1 (Figure 5A and B). Cell prolifera-
tion assays showed that knockdown of Notch1 decreased
the proliferation of MCF7-S100A16 cells (Figure 5C). Im-
portantly, knockdown of Notch1 decreased migration and
invasion in MCF7-S100A16 cells (Figure 5D and E). These
data indicated that Notch1 was a major regulator of EMT
and it might be an important target site to reduce migration
and invasion of breast cancer cells.
S100A16 activated Notch1 transcriptional activity
Since S100A16 was able to regulate expression of
Notch1 (Figure 4A and B), we addressed the question of
Figure 3 Overexpression of S100A16 promoted EMT in MCF-7 cells. (A) Compared with control cells (MCF7-GFP), MCF7-S100A16 cells showed
spindle-like, fibroblastic morphology (10×). (B, C) qRT-PCR (B) and western blot (C) analyses showed that epithelial markers E-cadherin and β-Catenin were
significantly reduced in mRNA and protein levels in MCF7-S100A16 cells compared with MCF7-GFP cells, and mesenchymal markers Vimentin and
N-cadherin were significantly up-regulated in MCF7-S100A16 cells (Bars, mean ± SD, P< 0.05). (D, E) Immunofluorescence staining was used to examine
the location of epithelial and mesenchymal markers. After fixation, the celluar location of E-cadherin (red), β-catenin (red), Vimentin (red) and N-cadherin
(red) were analyzed by confocal microscopy. Cell nuclei were stained with DAPI (4′, 6-diamidino-2-phenylindole, blue). Immunofluorescence staining
showed that both E-cadherin (red) and β-catenin (red) resided in the cell membrane and intensity of fluorescence were reduced in MCF7-S100A16 cells
compared with MCF7-GFP cells (D), whereas the mesenchymal markers Vimentin (red) and N-cadherin (red) were increased by S100A16 (E).
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the Notch1 promoter. In S100A16-transduced MCF-7
cells, transcriptional activities were increased in four
transfected plasmids (Figure 6). However, the region
from −1496 to +76 had the strongest promoter activity
(Figure 6). And it seemed that the region from −1496
to −998 was the core part accounting for increasing pro-
moter activity. This result confirmed that S100A16 could
regulate the transcriptional activity of the Notch1 pro-
moter in breast cancer cells.Discussion
S100A16 is a novel calcium-binding signaling protein of
the EF-hand superfamily [7]. It has been reported that
S100A16 is up-regulated in various malignant tumors
[5,9], however, the role of S100A16 gene in human breast
cancer is yet to be elucidated. In the present study, we first
documented here that overexpression of S100A16 oc-
curred in the human breast cancer tumors compared with
the paired adjacent normal tissue. This result encouraged
us to further investigate the function of S100A16 in the
Figure 4 Up-regulation of S100A16 increased Notch1, ZEB1 and ZEB 2 expression. (A, B) qRT-PCR (A) and western blot (B) analyses
showed that mRNA and protein levels of Notch 1, ZEB1 and ZEB2 were significantly enhanced in MCF7-S100A16 cells compared with control cells
(Bars, mean ± SD, P< 0.05). (C, D) Immunofluorescence staining was used to examine the location of two transcription factors ZEB1 and ZEB2. After fixation,
the celluar location of ZEB1 (red) and ZEB2 (red) were analyzed by confocal microscopy. Cell nuclei were stained with DAPI (4′, 6-diamidino-2-phenylindole,
blue). Immunofluorescence staining showed that two transcription factors ZEB1 (C) and ZEB2 (D) localized in the nucleus and the fluorescence signals
were enhanced after S100A16 up-regulation.
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that S100A16 promotes adipogenesis and is involved in
weight gain attenuation [7,8]. However, we found that
overexpression of the S100A16 gene increased prolifera-
tion, migration and invasion in MCF-7 cells, and induced
EMT in MCF-7 and T47D cells.
EMT is an invasive phenotype of cancer cells and in-
volved in the events of tumor progression and metasta-
ses [10,19]. Multiple transcriptional factors are regulated
in the process of EMT, demonstrating differentially in
different types of cells. In our cell model, overexpression
of S100A16 could up-regulate transcriptional factors
ZEB1 and ZEB2, which directly repressed the expression
of E-cadherin and enhanced expression of mesenchymal
markers E-cadherin and vimentin. All these data indi-
cated that the S100A16 gene might be closely associated
with EMT and promote invasion and metastases during
the progression of human breast cancer.
We sought to find the mechanisms how the S100A16
regulated ZEB1 and ZEB2 to promote EMT in this cell
model. Many studies confirm that ZEB1 and ZEB2 areable to repress E-cadherin in various cells [16-18], and
reversal of EMT requires inhibition of ZEB expression
[18]. Our recent observation suggests that Notch1 is
involved in the induction of EMT in a novel breast
cancer mouse model [19]. In agreement with this re-
sult, overexpression of S100A16 enhanced the levels
of Notch1 and regulated transcriptional activity of
Notch1 in breast cancer cells. Knockdown of Notch1
decreased the levels of ZEB1 and ZEB2. Importantly,
EMT was reversed after decreasing Notch1 expression
in the S100A16 overexpressed cell line. All of these re-
sults first indicated that Notch1 was the upstream of
ZEB and may play an important role in triggering
EMT in breast cancer cells. We first demonstrated
here that S100A16 overexpression induced EMT via
Notch1/ZEB pathway.
It is well known that EMT is a complicated process
with many pathways involving in, such as Wnt pathway,
TGF-β pathway, and Shh pathway etc. [10,20-22]. These
factors interact with each other to affect the phenotype
of cells. Among the tested cell lines, it was interesting to
Figure 5 Knockdown of Notch1 reversed EMT by decreasing ZEB1 and ZEB 2 expression. (A, B) Specific siRNA was used to knockdown
Notch1 in MCF7-S100A16 cells. qRT-PCR (A) and western blot (B) analyses showed that Notch1 was successfully knockdown. ZEB1 and ZEB2 were
significantly reduced in mRNA and protein levels after knockdown of Notch1. Consequently, epithelial markers E-cadherin and β-Catenin were
significantly increased but mesenchymal markers Vimentin and N-cadherin were reduced. There was no variation in the expression of S100A16
influenced by Notch1 knockdown. (Bars, mean ± SD, P < 0.05). (C) MTT assay showed that knockdown of Notch1 decreased the proliferation of
MCF7-S100A16 cells (Bars, mean ± SD, *P < 0.05, **P < 0.01). (D, E) Transwell migration and invasion assays showed knockdown of Notch1
decreased migration and invasion in MCF7-S100A16 cells (P < 0.05). Triplicate assays were used for each experiment (Magnification, 10×).
Zhou et al. Journal of Biomedical Science 2014, 21:97 Page 9 of 10
http://www.jbiomedsci.com/content/21/1/97find that S100A16 protein was mainly expressed in epithe-
lial breast cancer cell lines but not in mesenchymal breast
cancer cell lines. Moreover, expression of S100A16 was
detected in ER-positive cell line, HER2-positive cell line,
as well as triple-negative cell line. It is unclear the associ-
ation among S100A16, ER, and HER2 in breast cancer.
More investigation is required to find the relationship of
S100A16 with two important clinical biomarkers ER and
HER2 in breast cancer. It is also under study to follow upFigure 6 S100A16 activated Notch1 transcriptional activity. Dual lucife
increased in four transfected plasmids in S100A16-transduced MCF-7 cells (
had the strongest promoter activity. It seemed that the region from −1496the patients with S100A16 overexpresstion to confirm the
function of S100A16 in the progression of breast cancer.
Conclusions
In summary, the current study demonstrated that overex-
pression of S100A16 gene promoted EMT via Notch1/
ZEB1, ZEB2/EMT pathway in breast cancer cells. These
findings suggested that S100A16 could be a target for the
intervention of human breast cancer.rase reporter assay showed that transcriptional activities were
Bars, mean ± SD, P < 0.05). However, the region from −1496 to +76
to −998 was the core part accounting for increasing promoter activity.
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Additional file 1: Figure S1. Western blot analyses showed S100A16
protein expression was not detected in normal breast epithelial cells
184A1 and 184B5. Figure S2. Western blot analyses showed that
epithelial markers E-cadherin and β-Catenin were significantly reduced in
protein levels in T47D-S100A16 cells compared with T47D-GFP cells, and
mesenchymal markers Vimentin and N-cadherin were significantly
up-regulated in T47D-S100A16 cells. Figure S3. Transwell migration assay
showed that up-regulation of S100A16 increased cell migration abilities
in T47D breast cancer cells (P < 0.05). Figure S4. Transwell invasion assay
showed that up-regulation of S100A16 increased cell invasion abilities in
T47D breast cancer cells (P < 0.05).
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